ADVANCED SOLID TUMORS

This early-stage study tests a personalized cell therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow them in large numbers, and give them back through an IV. The goal is to see if…

This early-phase study tests an experimental pill called WJ22096 in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The main goals are to find a safe dose and see if the drug can shrink tumors. About 20 or more part…

This early-stage trial tests the safety and effectiveness of a new antibody called GEN1079 in 121 people with certain advanced solid tumors. The study has multiple parts to find the best dose and see if the drug shrinks tumors. All participants receive the active drug, and the tr…

This early-phase study tests a new drug (AT1019) combined with targeted radiation and an immunotherapy drug in people with advanced solid tumors. The main goal is to find a safe dose and check for side effects. About 12 participants will receive the treatment and be monitored clo…

This study tests a new drug called WEF-001 in about 110 adults with advanced solid tumors (pancreatic, colorectal, lung, ovarian, bile duct, or bladder cancer) that have a KRAS gene mutation and have stopped responding to standard treatments. The goal is to check the drug's safet…

This study is the first time VVD-130037 is being tested in humans. It aims to find out if the drug is safe and can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 290 participants will receive the drug alone or combin…

This early study is testing an experimental oral drug called ATX-295 in about 90 people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This study tests a combination of a special form of sirolimus (a drug that slows cancer growth) with different antibody-drug conjugates (ADCs, which deliver powerful medicine directly to cancer cells) in people with advanced solid tumors that cannot be removed by surgery or have …

This early-stage study tests a new drug called HW071021 in 76 adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have spread or come back. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the …

This study tests a new drug called BMS-986482, given alone or with other medicines, for people with advanced solid tumors that have not responded to standard treatments. About 413 adults will take part to see if the drug is safe and can shrink tumors. The goal is to find the best…

This early-stage study tests a new drug, GenSci139, in 280 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors. The study is currently recruiting.

This early-phase study tests a new drug called HWS116 in about 56 adults with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have worsened after standard treatments. The main goals are to check safety and see if the drug can shrink tumors. This is a f…

This early-phase study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if it can shrink tumors. About 272 people…

This early-stage study tests a new drug called VVD-159642, which blocks certain cancer-driving proteins. It is for adults with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have not responded to other treatments. The study will test the drug alone or wi…

This early-stage study tests a new drug called BAT8008 in about 182 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. Participants must have measu…

This early-stage trial tests a new drug called metarrestin in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumo…

This study tests a new drug called MK-3120 in about 270 people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to check the drug's safety and whether people can tolerate it. Participants must have already tried all available treatmen…

This study tests a new experimental drug called CKD-512, given alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 60 pa…

This early-phase study tests a new drug called 177Lu-RAD202 in 30 adults with advanced solid tumors that have a HER2 gene change. The drug uses a radioactive particle attached to an antibody to seek out and deliver radiation directly to cancer cells. The study first uses a small …

This study tests a new drug called ETX-636 in people with advanced solid tumors (like breast cancer) that have a specific genetic change (PIK3CA mutation). The goal is to see if the drug is safe and can shrink tumors, either alone or with another cancer drug. About 233 adults wil…

This study tests an experimental drug called marlotamig (REGN7075) alone and with cemiplimab (with or without chemo) in people with advanced solid tumors. The goal is to find the safest and most effective dose and see if the combination can shrink tumors or slow their growth. Abo…

This study tests a new drug called SHR-1826 combined with other cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. About 876 ad…

This early-phase study tests a new treatment called Meta10-TIL for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in the lab to better fight cancer. The main goal is to check saf…

This early-stage study tests a new pill called GEN-725 in 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose, while also looking at whether it can shrink tumors. Participants m…

This study tests an experimental drug, CM518D1, in about 434 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be clo…

This early-phase study tests an experimental oral drug, ST-01156, in adults with advanced solid tumors (including Ewing sarcoma, liver, and bile duct cancers) that have spread or cannot be removed. The main goals are to find a safe dose and understand side effects. Participants t…

This early-phase study tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein (Ly6E) found on certain cancer cells, including lung, breast, ovarian, head and neck, pancreatic, and…

This early-stage study is testing an experimental drug called BMS-986504 in Japanese and Chinese adults with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check the drug's safety and how the body processes it. About 32 participan…

This early-phase trial tests a new drug, TEV-56278, alone or with pembrolizumab, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 240 adul…

This early-stage study tests an experimental drug called BMS-986490, alone or with another drug (bevacizumab), in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to check safety and find the right dose. About 360 adults whose cancer has spread…

This early-phase study tests a new drug called BGM-2121 in about 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. This is a first-in-human trial, so it focuses on side effects …

This early-stage study tests a new cell therapy called NK042 in people with advanced solid tumors that have not responded to standard treatments. The goal is to check if it is safe and to see if it can shrink tumors. About 76 adults aged 18 to 70 will take part, receiving the tre…

This study tests whether combining two experimental drugs (RAS(ON) inhibitors and ivonescimab) is safe and can shrink tumors in adults with advanced solid cancers that have a RAS mutation. About 370 people with lung, colorectal, or other solid tumors that have worsened after stan…

This study tests a new drug called JAB-23E73 in adults with advanced solid tumors that have a specific genetic change (KRAS alteration). The main goals are to find safe doses and check for early signs that the drug can shrink tumors. About 294 participants will take part in this …

This early-stage study tests an experimental pill, VVD-133214, in people with advanced solid tumors that have a specific genetic feature (MSI or dMMR). The drug aims to block a protein that helps these cancers grow. The study will check safety and whether the drug shrinks tumors,…

This early-phase trial tests the safety and best dose of a new drug called SIBP-A19 in 156 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the maximum tolerated dose and any side effects. Participants must provide tumor sam…

This early-stage study tests a new drug called ASP1002 in adults with advanced solid tumors that have spread and have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants re…

This study tests a new drug called AMT-253 in people with advanced melanoma or other solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the drug can shrink tumors. About 96 participants will join this early-phase trial.

This early-stage trial tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety and find the right dose. About 240 adults whose cancer has worsened after…

This early-stage study tests a new drug called DB-1311/BNT324 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults with various ad…

This study tests a new drug called SPH4336, given alone or with another drug (cadonilimab), in people with advanced solid tumors that cannot be removed by surgery. The goal is to see if the treatment can slow tumor growth or shrink tumors. About 63 participants will take part in …

This early-phase study tests a new drug called ABX-001, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tu…

This early-stage study tests a new cell treatment called GK01 in people with advanced lung or esophageal cancer that hasn't responded to standard treatments. The main goal is to check if the treatment is safe and tolerable. Only 10 participants will be enrolled, and the study is …

This early-stage study tests a new drug called PHN-012, designed to deliver a powerful cancer-killing agent directly to tumor cells. It is for people with advanced colon, pancreatic, or lung cancer who have tried other treatments without success. The main goals are to check the d…

This study tests a new drug called FL115 combined with an immunotherapy (PD-1 blocker) in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About 130 adults aged 18-80 will receiv…

This early-phase study tests an injectable drug called SHR-3821 in 162 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must be 18-75, in fai…

This study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The goal is to see if the drug can shrink tumors and to check for side effects. It is an early-phase trial to gather ini…

This early-stage study tests a new drug called GS-2121, given alone or with another drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 154 participants will take …

This early-stage trial tests a new drug called E303 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the drug …

This early-stage study tests a new drug, SIM0505, in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 414 people will take part across multiple c…

This study tests a new drug called LCB84, which targets a protein (TROP2) on cancer cells, for people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or with another drug that boosts the immune system. The goal is to find sa…

This study tests a new medicine called SNV4818 for people with advanced solid tumors that have not responded to other treatments. The goal is to find the safest and most effective dose, either alone or with other cancer drugs. About 320 participants will take part in this early-p…

This study tests a new drug, XNW28012, in people with advanced solid tumors (like pancreatic, ovarian, or cervical cancer) who have not responded to or cannot tolerate standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 participan…

This study tests a new drug called WJB001 in people with advanced solid tumors who have no standard treatment options left. The goal is to find a safe dose and see if the drug can shrink tumors. About 210 adults will take part in three phases: starting with low doses to check saf…

This study tests a new drug called SPR1020 in 210 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells while causing fewer side effects, especially to the blood. The goal is to find the safest and most effec…

This early-stage study tests a new drug called SIGX1094R in about 102 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how it affects tumors. Researchers will also study h…

This early-phase study tests a new oral drug, TYRA-430, in people with advanced liver cancer or other solid tumors that have specific genetic changes (FGF/FGFR pathway). The main goals are to find the safest dose and check for side effects. About 100 adults will take part. This i…

This early-stage study tests an experimental drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V mutation. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tumors. About 574 participants will …

This study tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific change in the PI3K gene. The trial has two parts: first, finding the safest dose of OKI-219 alone, then testing it in combination with other cancer drugs. About 2…

This early-stage study tests a new drug called SKB445 in 126 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors or…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and s…

This study tests a new drug called RMC-6236 in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 754 people will take part, and the drug is…

This early-phase study tests a new drug called MGC028 in adults with advanced solid tumors (lung, bile duct, pancreas, or colon cancers) that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or stop the…

This early-phase study tests a new drug called AK146D1 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two targets on cancer cells to deliver a toxic payload directly. The main goals are to check safety and fi…

This study tests whether wearing a compression stocking on one foot during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by certain cancer drugs. About 58 adults with advanced cancers will take part, wearing a stocking on their left foot only during each dr…

This study is for people with advanced cancer (solid tumors, lymphoma, or multiple myeloma) that has stopped responding to standard treatments. Researchers want to see if giving a targeted drug that matches a specific gene change in the tumor can shrink the cancer or keep it stab…

This early-phase study looks at how a new drug called rezatapopt affects the way the body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C mutation. About 14 participants wil…